A comprehensive analysis of cytogenetics, molecular profile, and survival among pediatric acute myeloid leukemia : a prospective study from a tertiary referral center
AJBR Copyright © 2022..
BACKGROUND AND AIMS: The objectives of this study were to investigate the cyto-molecular profile and survival of pediatric acute myeloid leukemia (AML).
METHODS: This prospective study was carried out in a tertiary care hospital from October 2018 to December 2020. Karyotype and cytogenetics analyses were done to identify chromosomal aberrations in pediatric AML. The targeted molecular panel utilized the polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), and fragment analysis.
RESULTS: A total of 70 patients of AML with aged ≤18 years were enrolled in this study. The cytogenetic analyses revealed abnormal/recurrent cytogenetic abnormalities (CA) in 64.3% of patients and normal cytogenetics (CN) in 35.7% of patients. FAB M2 subtype showed frequent aberrant expression of the CD19 marker. CD7, CD11b, and CD36a were significantly present in the absence of molecular markers. Common chromosomal abnormalities were t(translocation) (8;21) (55%), monosomy/deletion 7 (13%), monosomal karyotype (5%) and complex karyotype (3%). The fusion transcripts RUNX1-RUNX1T1 [t(8;21)] (41%) and CBFB-MYH11 [t(16;16)] (3%) were detected by RT-PCR and FLT3-TKD D835 mutation (1.5%) by allele-specific oligo PCR. Fragment analysis revealed NPM1 (8%) mutation and FLT-ITD (9.5%) mutations. Complete remission was achieved in all evaluable patients. The median follow-up period of our patients was 225 days (IQR 28; 426 days). The median event-free survival (EFS) in all patients was 11.9 months (95% CI, 5-12.6 months). The forty months overall survival probability (pOS) was 58% in all patients.
CONCLUSION: The majority of patients had abnormal/recurrent cytogenetics abnormalities. FAB M2 subtype showed frequent aberrant expression of the CD19. The absence of molecular markers may suggest the presence of CD7, CD11b, and CD36a expression. The overall survival has increased considerably in LMIC.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
American journal of blood research - 12(2022), 6 vom: 28., Seite 177-189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meena, Jagdish Prasad [VerfasserIn] |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 07.02.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM352522844 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352522844 | ||
| 003 | DE-627 | ||
| 005 | 20231226205926.0 | ||
| 007 | tu | ||
| 008 | 231226s2022 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352522844 | ||
| 035 | |a (NLM)36742278 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meena, Jagdish Prasad |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comprehensive analysis of cytogenetics, molecular profile, and survival among pediatric acute myeloid leukemia |b a prospective study from a tertiary referral center |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 07.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJBR Copyright © 2022. | ||
| 520 | |a BACKGROUND AND AIMS: The objectives of this study were to investigate the cyto-molecular profile and survival of pediatric acute myeloid leukemia (AML) | ||
| 520 | |a METHODS: This prospective study was carried out in a tertiary care hospital from October 2018 to December 2020. Karyotype and cytogenetics analyses were done to identify chromosomal aberrations in pediatric AML. The targeted molecular panel utilized the polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), and fragment analysis | ||
| 520 | |a RESULTS: A total of 70 patients of AML with aged ≤18 years were enrolled in this study. The cytogenetic analyses revealed abnormal/recurrent cytogenetic abnormalities (CA) in 64.3% of patients and normal cytogenetics (CN) in 35.7% of patients. FAB M2 subtype showed frequent aberrant expression of the CD19 marker. CD7, CD11b, and CD36a were significantly present in the absence of molecular markers. Common chromosomal abnormalities were t(translocation) (8;21) (55%), monosomy/deletion 7 (13%), monosomal karyotype (5%) and complex karyotype (3%). The fusion transcripts RUNX1-RUNX1T1 [t(8;21)] (41%) and CBFB-MYH11 [t(16;16)] (3%) were detected by RT-PCR and FLT3-TKD D835 mutation (1.5%) by allele-specific oligo PCR. Fragment analysis revealed NPM1 (8%) mutation and FLT-ITD (9.5%) mutations. Complete remission was achieved in all evaluable patients. The median follow-up period of our patients was 225 days (IQR 28; 426 days). The median event-free survival (EFS) in all patients was 11.9 months (95% CI, 5-12.6 months). The forty months overall survival probability (pOS) was 58% in all patients | ||
| 520 | |a CONCLUSION: The majority of patients had abnormal/recurrent cytogenetics abnormalities. FAB M2 subtype showed frequent aberrant expression of the CD19. The absence of molecular markers may suggest the presence of CD7, CD11b, and CD36a expression. The overall survival has increased considerably in LMIC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a children | |
| 650 | 4 | |a cytogenetics | |
| 650 | 4 | |a karyotype | |
| 650 | 4 | |a molecular | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Makkar, Harshita |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Aditya Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhshi, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ritu |e verfasserin |4 aut | |
| 700 | 1 | |a Thakral, Deepshi |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Tanwar, Pranay |e verfasserin |4 aut | |
| 700 | 1 | |a Upadhyay, Ashish Datt |e verfasserin |4 aut | |
| 700 | 1 | |a Pathak, Nivedita |e verfasserin |4 aut | |
| 700 | 1 | |a Seth, Rachna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of blood research |d 2011 |g 12(2022), 6 vom: 28., Seite 177-189 |w (DE-627)NLM216338336 |x 2160-1992 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:6 |g day:28 |g pages:177-189 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 6 |b 28 |h 177-189 | ||